Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease.

Management of patients with interstitial lung disease (ILD) requires accurate classification. However, this process relies on subjective interpretation of nonspecific and overlapping clinical features that could hamper clinical care. The development and implementation of objective biomarkers reflective of specific disease states could facilitate precision-based approaches based on patient-level biology to improve the health of ILD patients. Omics-based studies allow for the seemingly unbiased and highly efficient screening of candidate biomarkers and offer unprecedented opportunities for discovery. This review outlines representative major omics-based discoveries in a well-studied condition, idiopathic pulmonary fibrosis, to develop a roadmap to personalized medicine in ILD. Copyright © 2021 Elsevier Inc. All rights reserved.

Citation

Chad A Newton, Erica L Herzog. Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease. Clinics in chest medicine. 2021 Jun;42(2):357-364

Mesh Tags

Substances

PMID: 34024410

search → result